Quantcast

Latest Diabetes management Stories

2014-06-17 08:30:51

WASHINGTON, June 17, 2014 /PRNewswire-USNewswire/ -- On January 13, the New York State (NYS) Department of Health issued a directive limiting the ways in which NYS medical laboratories can use blood glucose meters to help patients. Although AACC shares the Department's desire to ensure that blood glucose devices are used safely and appropriately, the association is concerned that this policy may impede the delivery of quality patient care and advises the Department to rescind it....

2014-06-17 08:30:49

User Demand for Dario(TM) Demonstrated with Purchase Orders, Positive Initial Customer Feedback and Initial Revenue Generated CAESAREA, Israel, June 17, 2014 /PRNewswire/ -- LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today provided a positive update on the initial "soft" launch of the Dario(TM) Smart Meter in the company's initial target jurisdictions of the United Kingdom, Italy and New Zealand. Dario(TM) is a cloud-based, diabetes...

New Study Finds Depression Misdiagnoses In Type 2 Diabetics
2014-06-17 08:07:14

Rebekah Eliason for redOrbit.com – Your Universe Online People suffering from diabetes are known to often struggle with depression as well. According to new research, the symptoms of depression among people with type 2 diabetes can significantly be reduced by interventions for “diabetes distress.” This finding suggests that what doctors are usually labeling as depression may not be a co-morbid psychiatric disorder. Instead researchers believe the depression may be a reaction to...

2014-06-16 20:22:11

AWARD-2: Once-Weekly Dulaglutide 0.75 mg Non-Inferior, 1.5 mg Superior in HbA1c Reduction from Baseline with Sustained Weight Loss and Lower Risk for Hypoglycemia SAN FRANCISCO, June 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from two AWARD trials that showed treatment with once-weekly dulaglutide 1.5 mg resulted in superior reductions in HbA1c from baseline compared to insulin glargine, with a lower risk for hypoglycemia.(1,2) Dulaglutide is an...

2014-06-16 18:01:02

Tonic Life Communications USA Presented at the American Diabetes Association Scientific Sessions Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development. Data from a clinical feasibility study demonstrated that the algorithm was capable of helping maintain glucose above hypoglycemic levels an average of 99.1 percent of the time for the 12 participants investigated, all of whom were adults with type 1 diabetes. The study...

2014-06-16 16:25:39

Phase 3 Study Results Also Demonstrate INVOKANA® Reduces Secondary Endpoints of Body Weight and Systolic Blood Pressure RARITAN, N.J., June 16, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced new results from a 104-week Phase 3 clinical study evaluating the long-term effects of INVOKANA(®) (canagliflozin) in patients aged 55 to 80 years with type 2 diabetes inadequately controlled on current antihyperglycemic therapies. The randomized double-blind...

2014-06-16 12:58:06

Merck Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc analysis showing that patients with type 2 diabetes having treatment intensified with insulin glargine therapy while also being treated with JANUVIA® (sitagliptin) 100 mg once-daily had a lower incidence of nighttime (nocturnal) hypoglycemia compared to patients also receiving placebo. Results were presented at the American Diabetes Association 74th Scientific Sessions....

2014-06-16 12:29:24

-- In a two-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in A1C (blood glucose), body weight and blood pressure compared with glimepiride as add-on to metformin RIDGEFIELD, Conn. and INDIANAPOLIS, June 16, 2014 /PRNewswire/ -- Two phase III clinical trials studying the efficacy and safety of the investigational compound empagliflozin in type 2 diabetes (T2D) were presented today at the American Diabetes Association 74th Scientific Sessions®,...

Diabetes Patients May Get Better Results With Bionic Pancreas
2014-06-16 10:23:47

Brett Smith for redOrbit.com - Your Universe Online A team of Massachusetts researchers working on a bionic pancreas were able to show that their device could maintain blood glucose levels consistently within the normal range, with fewer dangerous lows or highs, according to a paper published in the New England Journal of Medicine. The team said their device could make a massive difference in the lives of countless individuals coping with Type 1 diabetes. Conventional care for this kind...

2014-06-16 08:28:47

Algorithm in Development Maintained Glucose Above Hypoglycemic Levels Over 99% of Time in Feasibility Study CHESTERBROOK, Pa., June 16, 2014 /PRNewswire/ -- Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development. Data from a clinical feasibility study demonstrated that the algorithm was capable of helping maintain glucose above hypoglycemic levels an average of 99.1 percent of the time for the 12 participants investigated, all...


Latest Diabetes management Reference Libraries

Diabetes Care
2012-05-12 21:41:27

Diabetes Care is a peer-reviewed medical journal established in 1978 and published monthly by the American Diabetes Association. It covers research in the following five categories: clinical care/education/nutrition/psychosocial research; epidemiology/health services research; emerging treatments and technologies; pathophysiology/complications; and cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries....

More Articles (1 articles) »
Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related